Exosomes as a next-generation diagnostic and therapeutic tool in prostate cancer

Simita Gaglani, Edgar Gonzalez-Kozlova, Dara J. Lundon, Ashutosh K. Tewari, Navneet Dogra, Natasha Kyprianou

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Extracellular vesicles (EVs) have brought great momentum to the non-invasive liquid biopsy procedure for the detection, characterization, and monitoring of cancer. Despite the common use of PSA (prostate-specific antigen) as a biomarker for prostate cancer, there is an unmet need for a more specific diagnostic tool to detect tumor progression and recurrence. Exosomes, which are EVs that are released from all cells, play a large role in physiology and pathology, including cancer. They are involved in intercellular communication, immune function, and they are present in every bodily fluid studied—making them an excellent window into how cells are operating. With liquid biopsy, EVs can be isolated and analyzed, enabling an insight into a potential therapeutic value, serving as a vehicle for drugs or nucleic acids that have anti-neoplastic effects. The current application of advanced technology also points to higher-sensitivity detection methods that are minimally invasive. In this review, we discuss the current understanding of the significance of exosomes in prostate cancer and the potential diagnostic value of these EVs in disease progression.

Original languageEnglish
Article number10131
JournalInternational Journal of Molecular Sciences
Issue number18
StatePublished - Sep 2021


  • Biomarkers
  • Exosomes
  • Extracellular vesicles
  • Liquid biopsy
  • PSA
  • Prostate cancer
  • Therapeutic resistance


Dive into the research topics of 'Exosomes as a next-generation diagnostic and therapeutic tool in prostate cancer'. Together they form a unique fingerprint.

Cite this